• <strike id="xmwty"><table id="xmwty"></table></strike>
    <progress id="xmwty"></progress>

      <b id="xmwty"></b>

      ×

      Tonghua Dongbao announces NMPA acceptance of registration application for empagliflozin DS

      Date:2022-01-25
      Author:東寶
      Views:7

      Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received a notification of acceptance from the National Medical Products Administration (NMPA) on the registration application for empagliflozin drug substance (DS).

       

      Empagliflozin — a highly selective sodium glucose cotransporter-2 (SGLT-2) inhibitor — is a novel, non-insulin-dependent oral anti-diabetic drug that lowers the blood glucose in patients with type 2 diabetes mellitus (T2DM).

       

      With a unique, insulin-independent hypoglycemic mechanism, empagliflozin works by reducing the renal reabsorption of glucose, lowering the renal threshold for glucose, and increasing the urinary excretion of glucose. It can help protect the pancreatic β cells in patients with T2DM, lower their blood sugar and pressure, and mitigate the risk of hypoglycemia. According to the China Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition), empagliflozin can reduce the risk of major adverse cardiac events (MACE) by 14%, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, and hospitalization for heart failure in patients with T2DM.

       

      There is a huge market for empagliflozin, as it is on the fast track to sales growth in China. The brand-name empagliflozin recorded total sales of more than RMB 100 million in China's public medical institutions at all levels as well as urban pharmacies in 2020, up 374.64% from 2019, according to Menet.com, a Chinese medical information aggregator. Empagliflozin was included in China's national centralized volume-based procurement catalog in 2021, which will give a strong boost to its sales in Chinese public medical institutions. At the same time, the sales of empagliflozin across China's urban pharmacies are growing steadily. According to an International Diabetes Federation (IDF) report, China had reported 141 million diabetic patients in 2021, and the figure is expected to reach 164 million by 2030. This suggests that there is a huge demand for hypoglycemic drugs.

       

      The acceptance of the registration application for empagliflozin DS ensures a stable source of the active pharmaceutical ingredient for the Company's follow-up research on related preparations and new drug application. If the empagliflozin DS and related preparations are approved, the Company's diabetes drug portfolio will be expanded, providing diabetic patients with more medication options and boosting the Company's market presence.


      0 国产在线看片av免费,91中文字幕 国产,国产丝袜脚足j在线视频播放,黄视频在线观看无码免费
    1. <strike id="xmwty"><table id="xmwty"></table></strike>
      <progress id="xmwty"></progress>

        <b id="xmwty"></b>

        亚洲三区无码视频| 国产在线尤物不卡ab网站| 日躁夜躁狠狠躁2020| 中文字幕在线一区精品| 亚洲精品中文无线乱码| 成人精品鲁一区一区二区| 久青草国产在线视频97| 亚洲精品无码不卡在线资源| 色吊丝av熟女中文字幕| 一级少妇Av无码专区| 国产精品久国产精品| 91精品国产国语在线不卡| 久久久久国产综合| 国产在线视频天天综合网| 中文字幕之不卡无码视频| 久久久久狠狠夜夜躁| 中文字幕一二区二三区精品无码视频| 超碰伊人久久青草热| 久久激情无码免费综合视频| 日韩无码久久一区| 亚洲一级无码在线视频| 国产成人亚洲精品无码青青草原| 人妻和中文字幕无码系列| 每天更新的免费av片在线观看| 免费看国产夜色视频| 国产一区二区欧美日韩呦呦| 国产乱码精品一vv黄片| 精品人妻中文字幕有码在线| 久久久无码一区二区三区|